420 related articles for article (PubMed ID: 25733832)
1. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges.
Toporkiewicz M; Meissner J; Matusewicz L; Czogalla A; Sikorski AF
Int J Nanomedicine; 2015; 10():1399-414. PubMed ID: 25733832
[TBL] [Abstract][Full Text] [Related]
2. The ligand nanoparticle conjugation approach for targeted cancer therapy.
Karra N; Benita S
Curr Drug Metab; 2012 Jan; 13(1):22-41. PubMed ID: 21892918
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.
Fu Z; Xiang J
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266216
[TBL] [Abstract][Full Text] [Related]
5. A Review on Targeting Nanoparticles for Breast Cancer.
Alqaraghuli HGJ; Kashanian S; Rafipour R
Curr Pharm Biotechnol; 2019; 20(13):1087-1107. PubMed ID: 31364513
[TBL] [Abstract][Full Text] [Related]
6. Nanosize drug delivery system.
Mukherjee B
Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
[TBL] [Abstract][Full Text] [Related]
7. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
Zhong Y; Meng F; Deng C; Zhong Z
Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
[TBL] [Abstract][Full Text] [Related]
8. Actively Targeted Nanoparticles for Drug Delivery to Tumor.
Bi Y; Hao F; Yan G; Teng L; Lee RJ; Xie J
Curr Drug Metab; 2016; 17(8):763-782. PubMed ID: 27335116
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging and targeted therapy of cancer.
Vandghanooni S; Eskandani M; Barar J; Omidi Y
Eur J Pharm Sci; 2018 May; 117():301-312. PubMed ID: 29499349
[TBL] [Abstract][Full Text] [Related]
10. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity.
Liao D; Liu Z; Wrasidlo W; Chen T; Luo Y; Xiang R; Reisfeld RA
Nanomedicine; 2011 Dec; 7(6):665-73. PubMed ID: 21419870
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges.
He F; Wen N; Xiao D; Yan J; Xiong H; Cai S; Liu Z; Liu Y
Curr Med Chem; 2020; 27(13):2189-2219. PubMed ID: 30295183
[TBL] [Abstract][Full Text] [Related]
12. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions.
Park S; Kang S; Veach AJ; Vedvyas Y; Zarnegar R; Kim JY; Jin MM
Biomaterials; 2010 Oct; 31(30):7766-75. PubMed ID: 20667589
[TBL] [Abstract][Full Text] [Related]
13. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles and targeted drug delivery in cancer therapy.
Bahrami B; Hojjat-Farsangi M; Mohammadi H; Anvari E; Ghalamfarsa G; Yousefi M; Jadidi-Niaragh F
Immunol Lett; 2017 Oct; 190():64-83. PubMed ID: 28760499
[TBL] [Abstract][Full Text] [Related]
15. Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy.
Emami F; Duwa R; Banstola A; Woo SM; Kwon TK; Yook S
Biomed Pharmacother; 2023 Sep; 165():115023. PubMed ID: 37329708
[TBL] [Abstract][Full Text] [Related]
16. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
17. The choice of targets and ligands for site-specific delivery of nanomedicine to atherosclerosis.
Zia A; Wu Y; Nguyen T; Wang X; Peter K; Ta HT
Cardiovasc Res; 2020 Nov; 116(13):2055-2068. PubMed ID: 32077918
[TBL] [Abstract][Full Text] [Related]
18. Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
Kouchakzadeh H; Safavi MS; Shojaosadati SA
Adv Protein Chem Struct Biol; 2015; 98():121-43. PubMed ID: 25819278
[TBL] [Abstract][Full Text] [Related]
19. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated drug delivery.
Arslan FB; Ozturk Atar K; Calis S
Int J Pharm; 2021 Mar; 596():120268. PubMed ID: 33486037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
